, as we have also analysed US clinical trial registry data (ClinicalTrials.gov) 2 to study the same topic using data downloaded on 4 April 2007.
We identified 188,428 study sites for 8,143 industry-sponsored Phase I-IV trials (recruiting, no longer recruiting/ongoing or completed), compared with 123,713 sites for 6,046 studies identified by Thiers 4 . The number of study sites in the US thus increased by 143%, while all other 49 top-ranked countries showed an increase of at least 200% -with 20 countries showing an increase of more than 400%. Clearly, there was selective registration of trials with ClinicalTrials.gov prior to the implementation of the ICMJE policy in mid-2005.
We also downloaded the US trial register data on 1 November 2007 and kept for analysis industry-sponsored Phase II-IV trials (recruiting, no longer recruiting/ongoing or completed) with at least and FIG. 1 give our ranking of the top 50 countries based on the total number of study sites, as well as ranking based on annual growth, which differ from those presented in REF. 1 . Based on our results, Taiwan, Chile, Brazil, romania, Switzerland and the US had improved rankings of ten positions or more in annual growth of study sites, whereas Estonia, Portugal, Slovakia, Czech republic, Lithuania, Peru, Denmark and Japan all slipped down the rankings by 15 positions or more.
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